In 2022, the Global mRNA Vaccines and Therapeutics Market was valued at USD 71,263 million. It is expected to experience a compound annual growth rate (CAGR) of -34.01% between 2023 and 2028. The surge in demand for mRNA vaccines and therapeutics in the upcoming years can be attributed primarily to the heightened need for protection against sudden pandemic outbreaks, the expanding population of patients affected by infectious diseases globally, and the increase in the number of ongoing clinical trials for a range of medical conditions. Currently, some of the leading players in the Global mRNA Vaccines and Therapeutics Market include Pfizer Inc., BioNTech SE, Moderna, Inc., Gennova Biopharmaceuticals Limited, GSK plc., Daiichi Sankyo, Arcturus, Boehringer Ingelheim International GmbH, Ethris GmbH, CureVac SE, AIM Vaccine Corporation, Charoen Pokphand Group, Argos Therapeutics Inc., Sanofi, Kernal Biologics Inc, and others.
DelveInsight’s “mRNA Vaccines and Therapeutics Market Insight, Competitive Landscape and Market Forecast 2028” research report provides the current and forecasted mRNA Vaccines and Therapeutics market size, share, and trends analysis for the next five years. Moreover, it highlights the ongoing innovations in the segment, major market drivers & barriers, key competitors, and emerging devices in the domain.
mRNA Vaccines and Therapeutics Market: Overview
mRNA vaccines and therapeutics are a groundbreaking class of medical interventions that utilize messenger RNA (mRNA) molecules to trigger specific biological responses in the human body. These mRNA-based technologies have gained widespread attention and recognition, particularly due to their role in the development of COVID-19 vaccines.
mRNA Vaccines and Therapeutics Insights and their Applications:
mRNA Basics:
- mRNA is a molecule that carries genetic information from the DNA in the cell nucleus to the ribosomes, where proteins are synthesized.
- In the context of vaccines and therapeutics, synthetic mRNA is used, which carries instructions for the production of a specific protein.
mRNA Vaccines:
- mRNA vaccines work by introducing a small piece of synthetic mRNA that encodes a part of the target pathogen, such as a spike protein from a virus.
- Once the mRNA is injected into the body, cells in the immune system read the instructions and produce the target protein (e.g., the spike protein).
- The immune system recognizes this foreign protein as a threat and mounts an immune response, including the production of antibodies.
- These antibodies provide protection against future infections by the actual pathogen, as the immune system “remembers” how to fight it.
mRNA Therapeutics:
- mRNA therapeutics extend beyond vaccines. They can be used to treat various diseases by encoding proteins that can correct or replace malfunctioning or missing proteins in the body. For example, mRNA therapies are being explored for cancer treatment, where they can instruct cells to produce therapeutic proteins to stimulate the immune system or directly target cancer cells.
- mRNA therapies are also being researched for genetic disorders, where the mRNA provides instructions to produce the missing or defective protein.
Key advantages of mRNA vaccines and therapeutics include their rapid development process, adaptability to different pathogens, and potential for precise targeting. They do not contain live or weakened forms of the pathogen, reducing the risk of causing the disease they aim to protect against.
The COVID-19 pandemic saw the rapid development and deployment of mRNA vaccines (e.g., Pfizer-BioNTech and Moderna vaccines) that were shown to be highly effective in protecting against the SARS-CoV-2 virus. This success has spurred further research and development of mRNA-based therapies for various other diseases.
To provide a better understanding of the market dynamics, DelveInsight’s “mRNA Vaccines and Therapeutics Market” report provides an in-depth assessment of the market by vaccine type (self-amplifying mRNA-based vaccines and conventional non-amplifying mRNA-based vaccines), end-user (hospitals and clinics, research and development organizations, and others), and geography (North America, Europe, Asia-pacific, and rest of the world)
In the vaccine type segment of the mRNA vaccines and therapeutics market, it is anticipated that self-amplifying mRNA-based vaccines will significantly dominate the market in terms of revenue share in the forthcoming years. This can be primarily attributed to the numerous advantages they offer and the growing research and development activities dedicated to this category.
Self-amplifying mRNA-based vaccines offer several benefits, including ease of storage and reduced costs due to their inherent “self-amplifying” design, which allows for smaller dosage requirements. Ideally, a self-amplifying mRNA vaccine could replace the two primary doses typically administered during pandemics, providing a distinct advantage over conventional counterparts. While a booster dose months later may still be necessary, as is currently recommended for existing mRNA vaccines, self-amplifying mRNAs also hold the potential to elicit more long-lasting immune responses.
One of the primary drivers that contributed to the overall expansion of the mRNA vaccine and therapeutics market in recent years is the increasing need for vaccines to safeguard against unforeseen pandemic threats like COVID-19. During the height of the coronavirus crisis, when infection rates were rising steeply, both healthcare organizations and corporations dedicated significant efforts to expedite the research and development of mRNA vaccines. They also received financial support from various multinational companies and government entities to expedite the vaccine development process.
These vaccines play a crucial role in establishing immunity across the global population. COVID-19 vaccines have demonstrated remarkable effectiveness in shielding individuals from severe illness, hospitalization, and mortality. The innovative technology underlying mRNA vaccines is considered safe and aids in building immunity against infectious agents, including viruses. They achieve this by generating an antibody response without subjecting individuals to the risk of potentially severe illness.
Furthermore, the rising acceptance of mRNA vaccines and therapeutics, driven by heightened awareness, ongoing research endeavors, and increased financial backing, has enabled prominent corporations to enhance their innovative strategies for preventing and mitigating future disease outbreaks. This strategic shift is expected to not only boost the overall growth of the mRNA vaccines and therapeutics market in the years to come but also fortify global preparedness against emerging health threats.
Nonetheless, stringent regulatory approval requirements and the presence of established vaccines employing alternative technologies in the market, along with factors like vaccine hesitancy and production challenges, could pose obstacles to the growth of the mRNA vaccines and therapeutics market during the forecast period (2023-28). It’s important to acknowledge that while mRNA vaccines offer promising advantages, they face competition and regulatory scrutiny that may influence their market trajectory.
Interested to know more about the ongoing developments in the market? Visit to get an in-depth insight @ mRNA Vaccines and Therapeutics Types and Emerging Products
In the upcoming years, North America is anticipated to claim the foremost position in the mRNA vaccines and therapeutics market, holding the largest share among all regions. This regional dominance can be attributed to several factors, including the rising incidence of infectious diseases, exemplified by the ongoing COVID-19 pandemic, as well as the emergence of new cases related to conditions like monkeypox. The rise in the number of cases of monkeypox prompted increased research efforts by major companies in the region. This surge in monkeypox cases is poised to stimulate demand for mRNA vaccines during the forecast period.
Furthermore, North America has been a hub for dynamic vaccine development initiatives, contributing significantly to its prominent role in the market landscape. Ongoing mRNA vaccine development initiatives for various diseases across North America are expected to further expand the vaccine market in the foreseeable future.
Moreover, according to data from the Clinical Trials Government, there were approximately 150+ registered clinical trials involving biopharmaceuticals and mRNA vaccines in the United States in 2022. This substantial increase in the number of clinical trials focused on mRNA vaccines within the region is expected to serve as a significant catalyst for the market’s expansion. The surge in clinical research activities underscores the growing interest and investment in mRNA vaccine development, further solidifying North America’s role as a pivotal player in advancing this innovative medical technology.
Interested in knowing how the market will grow by 2028? Click to get a snapshot @ mRNA Vaccines and Therapeutics Market Trends and Developments
In recent years, the mRNA Vaccines and Therapeutics market has undergone substantial evolution, primarily driven by the active engagement of companies and notable technological progress in the field. Simultaneously, significant clinical, commercial, and regulatory advancements have been recorded within this domain. Some of the key developments in the mRNA Vaccines and Therapeutics sector in recent times are as follows:
- On September 14, 2023, Moderna, Inc. (NASDAQ: MRNA) announced business and clinical updates across its franchises and introduced several new development programs at the Company’s annual R&D Day. The Company has advanced a diverse pipeline and demonstrated the potential for clinical benefit in cancer (mRNA-4157), in three different rare diseases (mRNA-3705, mRNA-3927, mRNA-3745), and multiple infectious disease vaccines (mRNA-1273, mRNA-1345, mRNA-1010). The Company has advanced six programs into late-stage development, including two approved or filed for approval, and three more that have completed Phase 3 enrollment.
- In March 2023, Pfizer Inc. and BioNTech SE announced that the US Food and Drug Administration (FDA) granted emergency use authorization (EUA) to provide a single booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 4 years of age at least 2 months after completion of primary vaccination with three doses of the Pfizer-BioNTech COVID-19 Original Vaccine.
- In December 2022, Biopharmaceutical New Technologies (BioNTech) SE announced that the first subject was dosed in a Phase 1 clinical research study with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1. The first-in-human trial evaluates the safety, tolerability, and immunogenicity of BNT163.
- In September 2022, Pfizer Inc. announced that the first participants have been dosed in a pivotal Phase 3 clinical trial to evaluate the efficacy, safety, tolerability, and immunogenicity of the company’s quadrivalent modified influenza mRNA vaccine candidate in approximately 25,000 healthy US adults.
- In June 2022, Gennova Biopharmaceuticals launched its mRNA vaccine for COVID-19 named, Gemcovac-19 which can be stored at temperatures between 2°C and 8°C, and uses the mechanism of self-amplification.
- In August 2021, the US FDA announced the first approval of a COVID-19 mRNA vaccine manufactured by Pfizer and BioNTech known as the Pfizer-BioNTech COVID-19 vaccine for individuals 12 years of age and above.
Learn more about major clinical and commercial development in the market @ mRNA Vaccines Clinical and Commercial Development Activities
Companies play a pivotal role in shaping the landscape of the mRNA vaccines and therapeutics market. Their involvement spans from research and development to production, distribution, and regulatory compliance. Major pharmaceutical and biotechnology firms have actively spearheaded the development of mRNA-based vaccines, particularly highlighted during the COVID-19 pandemic with the rapid creation and distribution of mRNA vaccines like those from Pfizer-BioNTech and Moderna.
Globally, some of the leading MedTech giants working in the mRNA Vaccines and Therapeutics market include Pfizer Inc., BioNTech SE, Moderna, Inc., Gennova Biopharmaceuticals Limited, GSK plc., Daiichi Sankyo, Arcturus, Boehringer Ingelheim International GmbH, Ethris GmbH, CureVac SE, AIM Vaccine Corporation, Charoen Pokphand Group, Argos Therapeutics Inc., Sanofi, Kernal Biologics Inc, and others. Because of rising demand and the promising potential for revenue generation, it is anticipated that several newcomers will enter the market, leading to intensified competition in the industry.
These companies invest heavily in cutting-edge technologies and clinical trials to bring innovative mRNA therapies to market, addressing a wide range of diseases beyond infectious diseases, such as cancer and genetic disorders. Their financial and logistical resources are crucial for scaling up production and meeting global demand. Furthermore, collaborations between these companies and government agencies are vital for regulatory approvals, ensuring safety, and enhancing vaccine accessibility worldwide. As mRNA technology continues to evolve, these companies are instrumental in driving progress and enabling the application of mRNA vaccines and therapeutics to address current and future health challenges.
Learn how new players’ entries will transform the market dynamics in the coming years @ mRNA Vaccines and Therapeutics Competitive Landscape
Scope of the mRNA Vaccines and Therapeutics Market Report:
- Study Period – 2020-2028
- Geography Covered – North America, Europe, Asia-Pacific, and Rest of the World
- mRNA Vaccines and Therapeutics Market Assessment by –
-
-
- Vaccine Type – Self-Amplifying mRNA Based Vaccines and Conventional Non-Amplifying mRNA Based Vaccines
- End-User – Hospitals and Clinics, Research and Development Organizations, and Others
-
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s Views
Table of Content
| 1 | Report Introduction |
| 2 | Executive Summary |
| 3 | Regulatory and Patent Analysis |
| 4 | mRNA Vaccines and Therapeutics Market Key Factors Analysis |
| 5 | mRNA Vaccines and Therapeutics Porter’s Five Forces Analysis |
| 6 | COVID-19 Impact Analysis on the mRNA Vaccines and Therapeutics Market |
| 7 | mRNA Vaccines and Therapeutics Market Layout |
| 8 | mRNA Vaccines and Therapeutics Global Company Share Analysis – Key 3–5 Companies |
| 9 | mRNA Vaccines and Therapeutics Product Profiles and Key Companies |
| 10 | Project Approach |
| 11 | KOL Views |
| 12 | DelveInsight Capabilities |
| 13 | Disclaimer |
| 14 | About DelveInsight |
Reach out to us to get a more detailed overview of the market @ mRNA Vaccines and Therapeutics Market Insights and Competitive Landscape
Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at: Medical Devices Market Research
Other Trending Healthcare Reports by DelveInsight:
Acral Lentiginous Melanoma Market | Malt Lymphoma Market | Rhino Conjunctivitis Market | Defibrillators Market | Pulse Oximeters Market | Angioedema Market | Alopecia Aerata Market | Alopecia Areata Market | Bipolar Depression Market | Capnography Device Market | Bone And Joint Infection Market | Brain Aneurysm Stents Market | Hearing Aid Devices Market | Immunologic Deficiency Syndrome Market | Radiation Toxicity Market | Advanced Cancer Pain Management Market | Alport Syndrome Market | Pain Management Devices Market | Polycythemia Market | Vertigo Market | Actinic Keratosis Market | Acute Pulmonary Embolism Market | Ambulatory Arrhythmia Monitoring Devices Market | Aortic Stenosis Market | Chemotherapy Induced Thrombocytopenia Market | Dysthymia Market | Human Papillomavirus Positive Cancer Market | Onycholysis Market | Penicillinbinding Proteins Market | Postsurgical Pain Market | Desmoplastic Small Round Cell Tumors (dsrcts) Market | Hemophilia with Inhibitor Market | Pelvic Inflammatory Disease Market | Hemorrhoids Market | PCSK9 Inhibitors Market | Stargardt Disease (STGD) Market | Dravet Syndrome Market | Genital WartsMarket | Orthopedic Trauma Devices Market | Acute Lymphoblastic Leukemia (ALL) Market | Erythema Market | Primary Open Angle Glaucoma (POAG) Market | Familial Amyloid Polyneuropathy Market | Cutaneous Lupus Erythematosus Market | Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market | Traumatic Brain Injury Assessment Devices Market | Cartilage Diseases Market | Hormone Sensitive Advanced Prostate Cancer Market | Neuromodulation Devices Global Market | Cushing Syndrome Market | Germ Cell Tumor Market | Tonsillitis Market | Osteochondrodysplasias Market | Hemiplegia Market | Cart-related Neurotoxicity Market | Hematuria Market | Seborrhea Market | Inguinal Hernia Market | Emphysema Market | Diabetes Market | Seborrhoeic Dermatitis Market | Artificial Disc Market | Hernia Repair Devices Market | Peripheral Vascular Devices Market | Physiotherapy Equipment Market | Cardiac Monitoring System Market | Intracardiac Echocardiography Devices Market | Dental Laser Market
Discover DelveInsight’s Comprehensive Market Research and Consulting Services @ Healthcare Market Research
DelveInsight’s specialized oncology consulting solutions empower the pharma and biotech giants with tailored guidance and forefront proficiency, enabling adept navigation of ever-evolving clinical, commercial, and regulatory landscapes. Explore the key services and solutions @ Oncology Consulting Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
Manager (Marketing & Branding)
+1(919)321-6187.
